Results 41 to 50 of about 18,821 (231)

P2Y1 and P2Y12 receptor heterodimerisation : from recombinant systems to native detection [PDF]

, 2018
Purinergic P2Y1 and P2Y12 receptors belong to the class A family of transmembrane G‐protein coupled receptors (GPCRs) and have been demonstrated to exist as homodimers and oligomers and form heterodimers with other GPCRs.
Murray, J.F., Smith, C.L., Di Daniel, Elena, Bradley, S.J., Zuffa, S, Wood, R., Osman, A, Valant, C., Priestley, RS, Cunningham, M.R., Khajehali, E., Swann, J, Fagbodun, E, Priestley, Richard, Bailey, A, Davis, John, Molloy, C., Le Tissier, P., Kennedy, C., Ehebauer, MT, Patel, D, Tobin, A.B., Sexton, P.M., Di Daniel, E, Cheung, J, Armstrong, PC, Safar, M.A., Davis, JB, Berruien, N., Warner, TD, Thompson, K.J., Christopoulos, A., Murphy, EG, Cheung, Jonathan   +33 more
core   +1 more source

Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Journal of Interventional Cardiology, 2021
Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual antiplatelet therapies (DAPTs) after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods.
Yi Xu, Yimin Shen, Delong Chen, Pengfei Zhao, Jun Jiang   +4 more
doaj   +1 more source

Response variability to P2Y12 receptor inhibitors: expectations and reality.

JACC. Cardiovascular interventions, 2013
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity,
Siller-Matula, Jolanta M, Trenk, Dietmar, Schrör, Karsten, Gawaz, Meinrad, Kristensen, Steen D, Storey, Robert F, Huber, Kurt   +6 more
openaire   +4 more sources

Anti-platelet therapy: ADP receptor antagonists.

, 2011
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S, Wijeyeratne, YD, Stan Heptinstall, Yanushi Dullewe Wijeyeratne   +3 more
core   +1 more source

P2Y12 receptor modulation of ADP‐evoked intracellular Ca2+ signalling in THP-1 human monocytic cells [PDF]

, 2018
Background and purpose: The Gi‐coupled, ADP‐activated P2Y12 receptor is well characterised as playing a key role in platelet activation via crosstalk with P2Y1 in ADP‐evoked intracellular Ca2+ response.
J J Micklewright, J A Layhadi, Micklewright, J. J., Fountain, S. J., Layhadi, J. A., S J Fountain   +5 more
core   +1 more source

Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2017
Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI). With over 100 million prescriptions filled since its approval, clopidogrel is the most widely used P2Y12-receptor inhibitor.
Winter, MP, Grove, EL, De Caterina, R, Gorog, DA, Ahrens, I, Geisler, T, Gurbel, PA, Tantry, U, Navarese, EP, Siller-Matula, JM   +9 more
openaire   +5 more sources

Leukotriene E4 induces MUC5AC release from human airway epithelial NCI-H292 cells

Allergology International, 2015
Background: Hypersecretion of mucin in the airway epithelium is an important feature of allergic airway diseases. Of the 3 cysteinyl leukotrienes (CysLTs; LTC4 LTD4 and LTE4), only LTE4 is sufficiently stable to be detectable in extracellular fluids ...
Hideaki Shirasaki, Etsuko Kanaizumi, Nobuhiko Seki, Tetsuo Himi   +3 more
doaj   +1 more source

Antiplatelet therapy de-escalation in a patient after percutaneous coronary intervention with a high risk of bleeding

Российский кардиологический журнал, 2023
According to recommendations of ESC 2020-year, de-escalation of therapy with a P2Y12 receptor inhibitor (transition from prasugrel or ticagrelor to clopidogrel) It can be considered as an alternative strategy of dual antiplatelet therapy (DAPT) for ...
A. A. Kassymova, J. A. Mansurova, L. K. Karazhanova, A. A. Chinybayeva   +3 more
doaj   +1 more source

Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors

, 2014
Polypharmacy in patients undergoing coronary artery stenting or in those presenting with an acute coronary syndrome is common. Nevertheless, the risk of drug-drug interactions in patients treated simultaneously with P2Y12 receptor inhibitors is less well
Siller-Matula, Jolanta M., Krähenbühl, S., Delle-Karth, Georg, Siller-Matula, J. M., Delle-Karth, G., Michelson, Alan D., Trenk, Dietmar, Michelson, A. D., Trenk, D.   +8 more
core   +1 more source

Prmt6 Deficiency or Inhibition Restores Microglial Homeostasis and Promotes Scar‐Limited Repair in Adult Spinal Cord Injury

Advanced Science, EarlyView.
After spinal cord injury, adult microglia remain persistently activated with chronic PRMT6 (protein arginine methyltransferase 6) upregulation. Prmt6 deficiency or inhibition reestablishes microglial homeostasis and promotes a scar‐limited repairment, enhancing axonal regrowth.
Weilin Peng, Zhengqiang Wu, Yu Xiong, Zhongya Gao, Yishan Liu, Ziyi Wang, Haibin Wang, Chaofeng Han, Wenxiang Chu, Xuhua Lu   +9 more
wiley   +1 more source